A 24-month Randomised Parallel Group Single-blinded Multi-centre Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia

Trial Profile

A 24-month Randomised Parallel Group Single-blinded Multi-centre Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs AADvac 1 (Primary) ; Aluminium hydroxide
  • Indications Primary progressive aphasia
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms AIDA
  • Sponsors Axon Neuroscience
  • Most Recent Events

    • 12 Dec 2017 According to an Axon Neuroscience media release, an independent DSMB evaluated the safety data and concluded that during this period no safety concerns emerged and the enrollment can continue in both arms up to achieving the planned 30 patients.
    • 28 Aug 2017 Planned End Date changed from 1 Aug 2020 to 1 Jul 2020.
    • 28 Aug 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top